NL153271B - METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS. - Google Patents

METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS.

Info

Publication number
NL153271B
NL153271B NL696908269A NL6908269A NL153271B NL 153271 B NL153271 B NL 153271B NL 696908269 A NL696908269 A NL 696908269A NL 6908269 A NL6908269 A NL 6908269A NL 153271 B NL153271 B NL 153271B
Authority
NL
Netherlands
Prior art keywords
axenomycine
meoh
spectrum
complex
components
Prior art date
Application number
NL696908269A
Other languages
Dutch (nl)
Other versions
NL6908269A (en
Original Assignee
Farmaceutici Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutici Italia filed Critical Farmaceutici Italia
Publication of NL6908269A publication Critical patent/NL6908269A/xx
Publication of NL153271B publication Critical patent/NL153271B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07GCOMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G11/00Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • GPHYSICS
    • G21NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21FPROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F7/00Shielded cells or rooms
    • GPHYSICS
    • G21NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21HOBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
    • G21H5/00Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,219,709. The antibiotic axenomycine. SOC. FARMACEUTICI ITALIA. 6 June, 1969 [11 June, 1968], No. 28849/69. Heading C2A. The novel antibiotic axenomycine, also named F.I. 2604, is produced by cultivating Streptomyces lisandri n. sp., I.P.V 1951, I.M.R.U. 3935, I.M.I. 137178, or an axenomycine-producing strain thereof, under aerobic conditions in an aqueous medium containing assimilable sources of carbon and nitrogen and mineral salts, and isolating the axenomycine from the cultivated medium. The cultivation is preferably carried out at 23-37‹ C. and pH 6-9 for 60-160 hours. Axenomycine is a complex of two components, axenomycines A and B. The complex and its components are amorphous yellowish-white substances, soluble in methyl, ethyl and propyl alcohol, sparingly soluble in water, ethyl acetate, acetone and chloroform, and insoluble in benzene and petroleum ether. They reduce Fehling's solution and ammoniacal silver nitrate, give a positive reaction with tetrazole blue and a weakly positive Molisch reaction. They give negative reactions with ferric chloride, the aniline phthalate test for aldoses and the naphthoresorcinol test for ketoses. Axenomycine A has the following characteristics: elementary analysis, 61.74% C, 8.52% H, 28.87% O; molecular weight 1451.3; melting point 127-142‹ C. to give a transparent reddish gel; [&alpha;]<SP>23‹</SP> D = + 10À5‹ (C = 0.9 in MeOH); Rf = 0.49 on silica gel at pH 7.0 using n. butanol: acetic acid: water = 4: 0.5: 1; U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265-268 mÁ; I.R. spectrum in a KBr disc has peaks at 2.94, 3À44, 5.78, 6.00, 6.16, 6.24, 6.88, 7.25, 7.41, 8.61, 8.85, 9.35, 10.00, 10.40, 10.95, 11.8 and 12À5 Á. Axenomycine B has the characteristics: elementary analysis, 62.8% C., 8.58% H, 27.8% O; molecular weight 1330.2; melting point 122- 140‹ C.; [&alpha;]<SP>23‹</SP> D = + 5‹ (C = 0.9 in MeOH); Rf = 0À61 on silica gel at pH 7À0 using n. butanol: acetic acid: water = 4À0 : 0À5: 1; U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265- 268 mÁ; I.R. spectrum in a KBr disc has peaks at 2.94, 3À40, 5.82, 6.00, 6.16, 6.24, 6.86, 7.25, 7.41, 8.60, 8.85, 9.35, 10.00, 10.40, 10.98, 11.8, and 12À5 Á. The antibiotic complex may be extracted from the separated mycelium with e.g. methanol, or from the whole broth with a water-immiscible solvent, and purified by precipitation with a non-solvent followed by counter-current distribution. The two components may be separated by chromatography on a silica gel column at pH 7.0, developing with BuOH: HAc: H 2 O, 4: 0À5: 1 by volume. The antibiotics have anthelmintic, antiprotozoal and antifungal activity. Pharmaceutical compositions comprise axenomycine complex or one of its components A or B together with a pharmaceutically acceptable vehicle.
NL696908269A 1968-06-11 1969-05-30 METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS. NL153271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1757068 1968-06-11

Publications (2)

Publication Number Publication Date
NL6908269A NL6908269A (en) 1969-12-15
NL153271B true NL153271B (en) 1977-05-16

Family

ID=11150434

Family Applications (1)

Application Number Title Priority Date Filing Date
NL696908269A NL153271B (en) 1968-06-11 1969-05-30 METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS.

Country Status (16)

Country Link
AT (1) AT285817B (en)
BE (1) BE734341A (en)
BR (1) BR6909580D0 (en)
CH (1) CH506619A (en)
CS (1) CS178807B2 (en)
DE (1) DE1929107C3 (en)
DK (1) DK120716B (en)
ES (1) ES368198A1 (en)
FR (1) FR2010640A1 (en)
GB (1) GB1219709A (en)
IE (1) IE32866B1 (en)
IL (1) IL32358A (en)
NL (1) NL153271B (en)
NO (1) NO127927B (en)
SE (1) SE354483B (en)
YU (1) YU34212B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044819B (en) * 1970-05-04 1980-04-21 Farmaceutici Italia ANTIBIOTIC COMPOUND

Also Published As

Publication number Publication date
YU144469A (en) 1978-06-30
DK120716B (en) 1971-07-05
BE734341A (en) 1969-12-10
DE1929107C3 (en) 1978-10-12
FR2010640A1 (en) 1970-02-20
ES368198A1 (en) 1971-05-01
GB1219709A (en) 1971-01-20
NO127927B (en) 1973-09-03
DE1929107B2 (en) 1978-02-09
IE32866B1 (en) 1973-12-28
BR6909580D0 (en) 1973-04-19
AT285817B (en) 1970-11-10
IL32358A0 (en) 1969-08-27
DE1929107A1 (en) 1970-02-19
CS178807B2 (en) 1977-10-31
SE354483B (en) 1973-03-12
CH506619A (en) 1971-04-30
IE32866L (en) 1969-12-11
NL6908269A (en) 1969-12-15
YU34212B (en) 1979-02-28
IL32358A (en) 1972-11-28

Similar Documents

Publication Publication Date Title
Grove et al. The cytotoxicity of some transformation products of diacetoxyscirpenol
Takeuchi et al. Neothramycins A and B, new antitumor antibiotics
Nakamura Structure of azomycin, a new antibiotic
US3780173A (en) Partricin methyl ester
KR880010131A (en) Antibiotic vermisporin, preparation method thereof and pharmaceutical composition comprising the same as an active antimicrobial agent
Carter et al. Streptothricin. I. Preparation, Properties and Hydrolysis Products1
Rao et al. E-73: An antitumor substance. Part I. isolation and characterization1
NL153271B (en) METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS.
Kupchan Advances in the chemistry of tumor-inhibitory natural products
GB1349179A (en) Antibiotic
Kettner et al. Dactylarin, a new antiprotozoal antibiotic from Dactylaria lutea
Woelcke et al. Purine N-oxides. XXII. Structures of 3-hydroxyxanthine and guanine 3-oxide
Yamatodani et al. On Reduction of Agroclavine and Elymoclavine with Sodium and n-Butanol
GB1268394A (en) Method of purifying l-asparaginase
GB1116280A (en) Antibiotic a28829
TAMURA et al. Actinotiocin, a new sulfur-containing peptide antibiotic from Actinomadura pusilla
GB1310712A (en) Method for preparing monoacyl derivatives of antibiotic t-2636c
US3089816A (en) Lemacidine and process for its manufacture
Sano et al. Iyomycin, A New Antitumor Antibiotic from Streptomyces. III Isolation and Properties of Iyomycin B
Kaye Urethan carcinogenesis and nucleic acid metabolism: In vivo incorporation of pyrimidines-14C and urethan-14C into mouse organs
KITAGAWA et al. Studies on viomycin. VIII. Selective modifications of the terminal amino groups of viomycin
US3652535A (en) Kasugamycin derivatives
GB1378414A (en) Antibiotic compound and its preparation
SAWADA et al. Studies on the β-lysine peptide. IV. Preparation of semi-synthetic racemomycins and their antimicrobial activities
MURATA et al. THE ACTION OF BACTERIAL THIAMINASE I ON THIAMINE I. A DECOMPOSITION PRODUCT OF THIAMINE, PYRIMIDINYL-CYSTEINE

Legal Events

Date Code Title Description
VJC Lapsed due to non-payment of the due maintenance fee for the patent or patent application
NL80 Information provided on patent owner name for an already discontinued patent

Owner name: ITALIA